Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Bioxyne Limited ( (AU:BXN) ) is now available.
Bioxyne Limited has secured a manufacturing and supply agreement with Remidose LATAM SRL, marking its entry into the emerging medicinal cannabis markets of Costa Rica and Panama. This strategic move positions Bioxyne as a first-mover in these high-potential, low-competition markets, with the agreement potentially generating over A$1 million in annual revenue. The partnership underscores Bioxyne’s expertise in producing pharmaceutical-grade, non-flower formats like pastilles and aligns with their growth trajectory targeting significant revenue and EBITDA in FY26.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical manufacturer specializing in pharmaceutical-grade cannabis products. Through its subsidiary Breathe Life Sciences, Bioxyne focuses on producing high-quality THC pastilles and holds a strong position as a GMP-certified manufacturer.
Average Trading Volume: 2,972,812
Technical Sentiment Signal: Buy
Current Market Cap: A$81.02M
See more data about BXN stock on TipRanks’ Stock Analysis page.